← Back to Analyst Consensus 
KAPA Buy
Kairos Pharma, LTD.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Nov 19, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Nov 4, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Oct 20, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Oct 7, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Sep 19, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Jul 16, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Jun 4, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Apr 17, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Apr 3, 2025 | HC Wainwright & Co. | initiate | — → Buy | $12 | 44% |
| Mar 31, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Mar 27, 2025 | Maxim Group | initiate | — → Buy | $4 | 42% |
| Mar 20, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Feb 26, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Feb 18, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Feb 12, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Jan 22, 2025 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Nov 14, 2024 | D. Boral Capital | maintain | Buy → Buy | $9 | 34% |
| Oct 14, 2024 | EF Hutton | initiate | — → Buy | $9 | 30% |
Price Target Trend
Apr 25, 2026 Latest: $7 Oct 24, 2026
EPS Estimates
+1q $-0.11
Lo: $-0.11 Hi: $-0.11
1 analysts 0y $-0.37
Lo: $-0.37 Hi: $-0.37
1 analysts ▲1
0q $-0.09
Lo: $-0.09 Hi: $-0.09
1 analysts +1y $-0.67
Lo: $-0.67 Hi: $-0.67
1 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days